SpyGlass Pharma Inc SGP
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2026-02-06 |
| Shares Out. | 33,430,000 |
| Website | spyglasspharma.com/ ↗ |
| Phone | 13026587581 |
| Employees | 65 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$19.9M |
| Total Assets | $243.4M |
| Total Liabilities | $11.1M |
| Equity | $232.4M |
About SpyGlass Pharma Inc
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
SpyGlass Pharma Inc is a publicly traded company under the ticker symbol SGP on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-09-01)